Loading…
Loading…
VERO (Venus Concept Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
VERO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VERO and 80,000+ other tickers.
See exactly how VERO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VERO and 80,000+ other tickers.
Venus Concept Inc. is a medical technology firm that specializes in offering a range of innovative minimally and non-invasive solutions for medical aesthetics and hair restoration. Operating both domestically in the U.S. and internationally, the company is responsible for the development, market introduction, and ongoing provision of these advanced technologies and associated services. Its comprehensive product lineup features several cutting-edge devices: Venus Legacy: A non-invasive system primarily used in dermatological and general surgical procedures for female patients. Venus Versa: A…
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC's Doublo 2.0 device in the United States and Canada.
TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced changes to its senior leadership team.
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the successful completion by affiliates of Madryn Asset Management, LP (“Madryn”) of a short-form merger transaction, pursuant to which 100% ownership of the Company's common stock is now consolidated under funds managed by Madryn (the “Short-form Merger”). The Short-form Merger was consummated on March 30, 2026, and the Company is now privately held by Madryn. All common shares outstanding prior to the Short-form Merger (other than shares held directly or indirectly by Madryn) have been converted, subject to appraisal rights, into the right to receive $0.04 in cash, without interest and subject to applicable withholding.
Venus Concept Inc. (NASDAQ: VERO - Get Free Report) was the recipient of a large decline in short interest in January. As of January 30th, there was short interest totaling 72,826 shares, a decline of 57.8% from the January 15th total of 172,610 shares. Approximately 7.1% of the shares of the company are short sold. Based
TORONTO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) announced today its voluntarily decision to delist its common stock from the NASDAQ Capital Market (“Nasdaq”) and deregister its common stock with the Securities and Exchange Commission (the “SEC”).